Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy

NCT03010722 · clinicaltrials.gov ↗

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Regorafenib

Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

[object Object]